Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 443

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 443
---
 are listed below: • Exscientia (2022): an innovative license agreement and research collaboration to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples; • ABL Bio (2022) : a licensing and collaboration agreement for the development of ABL301, a bispecific antibody intended as a treatment for alpha-synucleinopathies; • Adagene Inc., a company specializing in the discovery and development of antibody-based therapies (2022) : collaboration and exclusive license agreement; • Blackstone (2022) : a strategic risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to € 300million to accelerate the global pivotal studies and clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma. That amount will be paid to Sanofi on the basis of development expenses incurred. In addition, Sanofi may pay royalties on future sales of this solution; • IGM Biosciences Inc. (2022) : an exclusive collaboration agreement to create, develop, manufacture and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets; • Atomwise (2022) : a collaboration agreement that will leverage Atomwise's ATOMNET platform to identify and synthesize up to five drug targets; • Scribe Therapeutics (2022) : a research collaboration to leverage Scribe's CRISPR by Design platform and to obtain a non- exclusive license to CasX-Editor(XE) genome editing technology for multiple oncology targets; • Insilico Medicine (2022) : a strategic research collaboration to leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new therapeutic targets; • Innate Pharma SA (2022) : an expanded collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7-H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform; • Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; • Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies; and • Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with